36316366|t|SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein.
36316366|a|Coronavirus disease-2019 (COVID-19) is primarily a respiratory disease, however, an increasing number of reports indicate that SARS-CoV-2 infection can also cause severe neurological manifestations, including precipitating cases of probable Parkinson's disease. As microglial NLRP3 inflammasome activation is a major driver of neurodegeneration, here we interrogated whether SARS-CoV-2 can promote microglial NLRP3 inflammasome activation. Using SARS-CoV-2 infection of transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) as a COVID-19 pre-clinical model, we established the presence of virus in the brain together with microglial activation and NLRP3 inflammasome upregulation in comparison to uninfected mice. Next, utilising a model of human monocyte-derived microglia, we identified that SARS-CoV-2 isolates can bind and enter human microglia in the absence of viral replication. This interaction of virus and microglia directly induced robust inflammasome activation, even in the absence of another priming signal. Mechanistically, we demonstrated that purified SARS-CoV-2 spike glycoprotein activated the NLRP3 inflammasome in LPS-primed microglia, in a ACE2-dependent manner. Spike protein also could prime the inflammasome in microglia through NF-kappaB signalling, allowing for activation through either ATP, nigericin or alpha-synuclein. Notably, SARS-CoV-2 and spike protein-mediated microglial inflammasome activation was significantly enhanced in the presence of alpha-synuclein fibrils and was entirely ablated by NLRP3-inhibition. Finally, we demonstrate SARS-CoV-2 infected hACE2 mice treated orally post-infection with the NLRP3 inhibitory drug MCC950, have significantly reduced microglial inflammasome activation, and increased survival in comparison with untreated SARS-CoV-2 infected mice. These results support a possible mechanism of microglial innate immune activation by SARS-CoV-2, which could explain the increased vulnerability to developing neurological symptoms akin to Parkinson's disease in COVID-19 infected individuals, and a potential therapeutic avenue for intervention.
36316366	0	10	SARS-CoV-2	Species	2697049
36316366	18	23	NLRP3	Gene	114548
36316366	51	56	human	Species	9606
36316366	90	114	Coronavirus disease-2019	Disease	MESH:D000086382
36316366	116	124	COVID-19	Disease	MESH:D000086382
36316366	141	160	respiratory disease	Disease	MESH:D012140
36316366	217	237	SARS-CoV-2 infection	Disease	MESH:D000086382
36316366	260	287	neurological manifestations	Disease	MESH:D009461
36316366	331	350	Parkinson's disease	Disease	MESH:D010300
36316366	366	371	NLRP3	Gene	114548
36316366	417	434	neurodegeneration	Disease	MESH:D019636
36316366	465	475	SARS-CoV-2	Species	2697049
36316366	499	504	NLRP3	Gene	114548
36316366	536	556	SARS-CoV-2 infection	Species	
36316366	571	575	mice	Species	10090
36316366	587	592	human	Species	9606
36316366	593	624	angiotensin-converting enzyme 2	Gene	59272
36316366	638	646	COVID-19	Disease	MESH:D000086382
36316366	757	762	NLRP3	Gene	114548
36316366	817	821	mice	Species	10090
36316366	850	855	human	Species	9606
36316366	903	913	SARS-CoV-2	Species	2697049
36316366	942	947	human	Species	9606
36316366	1178	1188	SARS-CoV-2	Species	2697049
36316366	1189	1207	spike glycoprotein	Gene	
36316366	1222	1227	NLRP3	Gene	114548
36316366	1244	1247	LPS	Chemical	MESH:D008070
36316366	1271	1275	ACE2	Gene	59272
36316366	1294	1307	Spike protein	Gene	
36316366	1363	1372	NF-kappaB	Gene	4790
36316366	1424	1427	ATP	Chemical	MESH:D000255
36316366	1429	1438	nigericin	Chemical	MESH:D009550
36316366	1442	1457	alpha-synuclein	Gene	6622
36316366	1468	1478	SARS-CoV-2	Species	2697049
36316366	1483	1496	spike protein	Gene	
36316366	1587	1602	alpha-synuclein	Gene	6622
36316366	1639	1644	NLRP3	Gene	114548
36316366	1681	1700	SARS-CoV-2 infected	Disease	MESH:D000086382
36316366	1701	1706	hACE2	CellLine	CVCL:B1U4
36316366	1707	1711	mice	Species	10090
36316366	1732	1741	infection	Disease	MESH:D007239
36316366	1751	1756	NLRP3	Gene	216799
36316366	1773	1779	MCC950	Chemical	MESH:C000597426
36316366	1896	1915	SARS-CoV-2 infected	Disease	MESH:D000086382
36316366	1916	1920	mice	Species	10090
36316366	2007	2017	SARS-CoV-2	Species	2697049
36316366	2081	2102	neurological symptoms	Disease	MESH:D009461
36316366	2111	2130	Parkinson's disease	Disease	MESH:D010300
36316366	2134	2151	COVID-19 infected	Disease	MESH:D000086382
36316366	Negative_Correlation	MESH:C000597426	216799
36316366	Negative_Correlation	MESH:C000597426	MESH:D000086382
36316366	Association	114548	59272
36316366	Negative_Correlation	MESH:C000597426	MESH:D007239
36316366	Association	MESH:D019636	114548

